vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and KINGSTONE COMPANIES, INC. (KINS). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $56.4M, roughly 1.4× KINGSTONE COMPANIES, INC.). KINGSTONE COMPANIES, INC. runs the higher net margin — 26.2% vs -9.6%, a 35.8% gap on every dollar of revenue. On growth, KINGSTONE COMPANIES, INC. posted the faster year-over-year revenue change (34.0% vs -16.8%). Over the past eight quarters, KINGSTONE COMPANIES, INC.'s revenue compounded faster (25.6% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Kingstone Companies, Inc., headquartered in Kingston, New York, provides property and casualty insurance products through its subsidiary, Kingstone Insurance Company. It places contracts with the third-party licensed premium finance company through its subsidiary Payments, Inc., a NYS licensed Insurance Premium Finance Company. Kingstone Insurance Company was ranked #1 of the 81 insurers rated by the Professional Insurance Agents Association in its 2010 Company Performance Survey. The company...

BIOX vs KINS — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.4× larger
BIOX
$77.6M
$56.4M
KINS
Growing faster (revenue YoY)
KINS
KINS
+50.8% gap
KINS
34.0%
-16.8%
BIOX
Higher net margin
KINS
KINS
35.8% more per $
KINS
26.2%
-9.6%
BIOX
Faster 2-yr revenue CAGR
KINS
KINS
Annualised
KINS
25.6%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
KINS
KINS
Revenue
$77.6M
$56.4M
Net Profit
$-7.4M
$14.8M
Gross Margin
46.8%
Operating Margin
9.3%
32.7%
Net Margin
-9.6%
26.2%
Revenue YoY
-16.8%
34.0%
Net Profit YoY
-20.2%
171.4%
EPS (diluted)
$-0.12
$1.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
KINS
KINS
Q4 25
$56.4M
Q3 25
$77.6M
$55.7M
Q2 25
$52.3M
Q1 25
$60.6M
$50.5M
Q4 24
$98.8M
$42.1M
Q3 24
$93.3M
$40.8M
Q2 24
$36.5M
Q1 24
$84.0M
$35.8M
Net Profit
BIOX
BIOX
KINS
KINS
Q4 25
$14.8M
Q3 25
$-7.4M
$10.9M
Q2 25
$11.3M
Q1 25
$-1.6M
$3.9M
Q4 24
$605.2K
$5.4M
Q3 24
$-6.2M
$7.0M
Q2 24
$4.5M
Q1 24
$9.8M
$1.4M
Gross Margin
BIOX
BIOX
KINS
KINS
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
KINS
KINS
Q4 25
32.7%
Q3 25
9.3%
24.6%
Q2 25
27.1%
Q1 25
1.5%
9.3%
Q4 24
14.5%
15.9%
Q3 24
2.5%
22.3%
Q2 24
15.7%
Q1 24
15.7%
5.0%
Net Margin
BIOX
BIOX
KINS
KINS
Q4 25
26.2%
Q3 25
-9.6%
19.5%
Q2 25
21.5%
Q1 25
-2.6%
7.7%
Q4 24
0.6%
12.9%
Q3 24
-6.6%
17.1%
Q2 24
12.4%
Q1 24
11.6%
4.0%
EPS (diluted)
BIOX
BIOX
KINS
KINS
Q4 25
$1.09
Q3 25
$-0.12
$0.74
Q2 25
$0.78
Q1 25
$-0.02
$0.27
Q4 24
$0.00
$0.44
Q3 24
$-0.10
$0.55
Q2 24
$0.37
Q1 24
$0.14
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
KINS
KINS
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
$4.4M
Stockholders' EquityBook value
$288.3M
$122.7M
Total Assets
$734.9M
$453.4M
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
KINS
KINS
Q4 25
Q3 25
$15.5M
Q2 25
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
Q1 24
$16.4M
Total Debt
BIOX
BIOX
KINS
KINS
Q4 25
$4.4M
Q3 25
$4.8M
Q2 25
$5.1M
Q1 25
$5.4M
Q4 24
$11.2M
Q3 24
$17.3M
Q2 24
$25.3M
Q1 24
$25.3M
Stockholders' Equity
BIOX
BIOX
KINS
KINS
Q4 25
$122.7M
Q3 25
$288.3M
$107.7M
Q2 25
$94.9M
Q1 25
$345.0M
$82.2M
Q4 24
$346.3M
$66.7M
Q3 24
$346.0M
$59.7M
Q2 24
$40.8M
Q1 24
$348.5M
$35.7M
Total Assets
BIOX
BIOX
KINS
KINS
Q4 25
$453.4M
Q3 25
$734.9M
$428.6M
Q2 25
$393.4M
Q1 25
$798.2M
$385.4M
Q4 24
$835.2M
$374.9M
Q3 24
$827.3M
$347.0M
Q2 24
$319.8M
Q1 24
$836.1M
$318.3M
Debt / Equity
BIOX
BIOX
KINS
KINS
Q4 25
0.04×
Q3 25
0.04×
Q2 25
0.05×
Q1 25
0.07×
Q4 24
0.17×
Q3 24
0.29×
Q2 24
0.62×
Q1 24
0.71×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
KINS
KINS
Operating Cash FlowLast quarter
$14.4M
$75.9M
Free Cash FlowOCF − Capex
$73.1M
FCF MarginFCF / Revenue
129.5%
Capex IntensityCapex / Revenue
5.0%
Cash ConversionOCF / Net Profit
5.14×
TTM Free Cash FlowTrailing 4 quarters
$124.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
KINS
KINS
Q4 25
$75.9M
Q3 25
$14.4M
$25.9M
Q2 25
$9.3M
Q1 25
$23.3M
$17.9M
Q4 24
$-5.4M
$57.9M
Q3 24
$5.2M
$21.7M
Q2 24
$7.1M
Q1 24
$-17.4M
$6.1M
Free Cash Flow
BIOX
BIOX
KINS
KINS
Q4 25
$73.1M
Q3 25
$25.3M
Q2 25
$8.7M
Q1 25
$17.0M
Q4 24
$55.6M
Q3 24
$21.0M
Q2 24
$6.6M
Q1 24
$5.6M
FCF Margin
BIOX
BIOX
KINS
KINS
Q4 25
129.5%
Q3 25
45.4%
Q2 25
16.6%
Q1 25
33.7%
Q4 24
132.1%
Q3 24
51.6%
Q2 24
18.1%
Q1 24
15.5%
Capex Intensity
BIOX
BIOX
KINS
KINS
Q4 25
5.0%
Q3 25
1.2%
Q2 25
1.1%
Q1 25
1.7%
Q4 24
5.6%
Q3 24
1.7%
Q2 24
1.4%
Q1 24
1.5%
Cash Conversion
BIOX
BIOX
KINS
KINS
Q4 25
5.14×
Q3 25
2.38×
Q2 25
0.82×
Q1 25
4.60×
Q4 24
-8.85×
10.65×
Q3 24
3.12×
Q2 24
1.58×
Q1 24
-1.78×
4.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons